Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD

Parent1 subsidiaryUEI: EUKJBSS2CEH3CAGE: QC370

NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD is a federal contractor, registered under UEI EUKJBSS2CEH3 and CAGE code QC370. It has been awarded $251,143 in federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services (hhs).

Contact Information

Registration and classification details

Registration

UEI Code

EUKJBSS2CEH3

CAGE Code

QC370

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

HospitalNon-Profit Organization

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

National Cancer Centre of Singapore Pte Ltd is a specialized research and clinical services organization focused on oncology care, translational research, and precision medicine initiatives. Its core capabilities center on advanced cancer diagnostics, multimodal therapeutic development, and data-dri...

National Cancer Centre of Singapore Pte Ltd is a specialized research and clinical services organization focused on oncology care, translational research, and precision medicine initiatives. Its core capabilities center on advanced cancer diagnostics, multimodal therapeutic development, and data-driven clinical trial design, leveraging genomic profiling, radiomics, and AI-assisted tumor analysis to deliver personalized patient care pathways. The organization excels in integrating laboratory research with clinical practice, operating high-compliance biospecimen repositories, molecular pathology labs, and multidisciplinary tumor boards. Key differentiators include its expertise in Asian-specific cancer epidemiology, biomarker validation for targeted therapies, and the operationalization of real-world evidence into clinical decision support systems. No agency relationships can be inferred from available award data, as no contract history with government entities is documented. The organization’s work appears to be primarily institutionally funded and clinically oriented, with no identifiable patterns of engagement with federal, state, or international public sector agencies. No NAICS categories are applicable based on the absence of contract award data. In practice, the organization operates at the intersection of biomedical research and tertiary healthcare delivery, with a vertical specialization in oncology services rather than commercial government contracting. Its market positioning is that of a world-class academic medical center focused on cancer innovation, not a provider of goods or services under public procurement frameworks. The entity is structured as a 2L organization based in Singapore, with no publicly listed government certifications. Its geographic presence is confined to Singapore, where it functions as a national reference center for cancer care and research. While it maintains rigorous clinical and research standards, it does not appear to be registered or certified for participation in government contracting programs.

Key Performance Metrics

Awards Count

25

All time

Active

0

Currently performing

Completed

25

Past period of performance

Total Awards

All time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
- Unknown NAICS$251.1K100%
Awards by Agency Over Time
Awards by Place of Performance

Subsidiaries

1 company rolls up into NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD, sized by each one's own awards

See all

Compete with NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD's top NAICS codes and agencies

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
The NIH Small Business Technology Transfer (STTR) grant, solicitation PA-27-102, provides early-stage funding for U.S. small business concerns (SBCs) to conduct research and development of commercial products in formal collaboration with non-profit research institutions. The program is designed to enhance health and reduce illness through a phased approach: Phase I focuses on establishing technical merit and feasibility, while Phase II advances the research toward commercialization. Eligible applicants must be for-profit entities located in the U.S., owned more than 50 percent by U.S. citizens or permanent residents, and employ no more than 500 people. The program accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with the latter two being NIH-specific options to accelerate development. Funding limits vary by the awarding NIH Institute or Center, with Phase I budgets typically ranging from 400,000 to 700,000 dollars and Phase II budgets reaching up to 3,000,000 dollars. Applications are evaluated via a peer review system based on an overall impact score, considering commercial potential, technical feasibility, and the quality of the commercialization plan. While clinical trials are generally optional, they require a specific regulatory plan and adherence to strict safety and registration guidelines; notably, several institutes, including NIAID and NIAMS, do not accept clinical trials under this NOFO. Applicants must maintain active registrations in SAM, possess a Unique Entity Identifier, and comply with cybersecurity incident reporting requirements, including notifying HHS within 48 hours of a discovery.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 6 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
The NIH, CDC, and FDA Small Business Innovation Research (SBIR) Grant, solicitation PA-27-100, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products. The program is structured in phases, with Phase I focusing on establishing technical merit and feasibility, and Phase II advancing the project toward commercialization. Eligible applicants include for-profit U.S. businesses with no more than 500 employees. The funding opportunity accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with the latter two being specific to the NIH. Budget limits vary by participating institute, with Phase I awards typically ranging from 400,000 to 700,000 dollars and Phase II awards reaching up to 3,000,000 dollars. Applications are evaluated through a peer review system based on scientific and technical merit, significance, and the suitability of the environment for success. While clinical trials are generally optional, they are prohibited for specific components, including all FDA centers and several NIH institutes such as NIAMS and NIDCR. Recipients must adhere to strict compliance requirements, including maintaining active SAM registration, disclosing foreign relationships, and implementing cybersecurity incident reporting procedures that notify agencies within 48 hours of discovery. All applications must be submitted electronically, with a final expiration date of April 06, 2027.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 6 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The SBIR/STTR Commercialization Readiness Pilot (CRP) Program, solicitation PAR-27-098, is a funding opportunity provided by the National Institutes of Health (NIH) to help U.S.-based small business concerns transition technology from late-stage research and development to full commercialization. This program is specifically available to recipients of prior or active NIH SBIR or STTR Phase II or Phase IIB Strategic Breakthrough awards. The CRP supports activities that bridge the gap to market, including technical assistance for regulatory and intellectual property strategies, manufacturing scale-up, independent replication of key studies, and clinical trials. While significant outsourcing to contract research organizations is permitted, the small business must maintain a substantial role in project oversight and management. Eligible applicants must be for-profit organizations with no more than 500 employees and maintain active registrations in the System for Award Management and the SBA Company Registry. Project periods are limited to a maximum of three years, with budget ceilings varying by participating Institute or Center, ranging from 500,000 dollars to 2 million dollars, or following SBA guidelines for certain institutes. Applications are evaluated via NIH peer review based on scientific and technical merit, commercial potential, and relevance to program priorities. Key submission requirements include a detailed regulatory plan and a CRP progress report, while costs for patent or FDA filing fees and separate Technical and Business Assistance funding are strictly prohibited.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 6 months
View Details